CareDx, Inc.

As of October 17, 2025, CareDx, Inc. has improved its valuation outlook to very attractive, appearing undervalued with favorable metrics compared to peers, despite its current loss-making status.

As of October 17, 2025, CareDx, Inc. is considered very attractive in valuation despite being loss-making, with a Price to Book Value of 2.87 and an EV to Capital Employed ratio of 5.58, while underperforming the S&P 500 with a year-to-date return of -32.70%.

As of October 10, 2025, CareDx, Inc. has a valuation grade of "very attractive" despite being overvalued with a Price to Book Value of 2.87 and a negative EV to EBIT ratio of -27.94, while its stock has declined by 52.87% over the past year, underperforming the S&P 500's 13.36% gain.

As of September 2, 2025, CareDx, Inc. has shifted to a bearish trend with weak strength indicators, underperforming the S&P 500 with a 1-year return of -49.52% compared to its 17.14%.

As of July 7, 2025, CareDx, Inc. is considered undervalued with a price of 14.77, significantly lower than its 52-week high of 32.97, and despite a 49.52% decline over the past year, its valuation ratios suggest potential for growth compared to peers like Organogenesis and Castle Biosciences.

As of February 26, 2025, CareDx, Inc. is considered very attractive and undervalued at $18.95, with a significant improvement in valuation despite a negative ROCE of -19.95% and a negative P/E ratio of -58.59%, outperforming the S&P 500 with a 34.78% return over the past year.

As of June 18, 2025, the market trend is neutral with mixed signals: weekly indicators show mild bullishness while monthly indicators are mildly bearish, indicating a lack of strong directional momentum.

As of March 2022, the management team of CareDx, Inc. includes Dr. Peter Maag (Executive Chairman), Dr. Reginald Seeto (CEO), and several independent directors, including Mr. Michael Goldberg, Mr. George Bickerstaff, Dr. Frederick Cohen, Dr. Grace Colon, and Ms. Christine Cournoyer. They collectively guide the company's strategic direction.

CareDx, Inc. is a molecular diagnostics company specializing in diagnostic surveillance solutions for transplant patients, with recent net sales of $85 million and a market cap of approximately $1.09 billion. The company reported a net profit loss of $10 million as of March 2025.

As of Jun 18, CareDx, Inc. has a market capitalization of $1.09 billion, with net sales of $346.42 million and a net profit of $68.55 million over the latest four quarters.